Marcelo C Shibata1, Jordan Curl-Roper2, Dirk J Van Veldhuisen3, Michael Roughton4, Andrew J S Coats5, Marcus Flather2. 1. University of Alberta, and Covenant Health, Misericordia Hospital, Suite 362, Heritage Medical Research Centre, Edmonton, AB, T6G 2C8, Canada. marcelo.shibata@ualberta.ca. 2. University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK. 3. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Novartis Campus, Basel, Switzerland. 5. Monash University, Melbourne, Australia.
Abstract
BACKGROUND: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the effect of nebivolol on 6MWT from the SENIORS trial. METHODS AND RESULTS: The SENIORS trial evaluated nebivolol versus placebo on death and hospitalisation in patients aged ≥ 70 years with heart failure. A total of 1982 patients undertook a 6MWT at baseline and 1716 patients at 6 months. Patients were divided into tertiles (≤ 200 m, 201 to ≤ 300 m and > 300 m) and to change in distance walked between baseline and 6 months (< 0 m, 0 to < 30 m and ≥ 30 m). The primary outcome was all-cause mortality and cardiovascular hospital admission. Secondary endpoint was all-cause mortality. Baseline walk distance of ≤ 200 m incurred a greater risk of the primary and secondary outcomes (HR 1.41, CI 95% 1.17-1.69, p < 0.001) and (HR 1.37, CI 95% 1.05-1.78, p = 0.019). A decline in walk distance over 6 months was associated with increased risk of clinical events. Nebivolol had no influence on change in walk distance over 6 months. CONCLUSIONS: The 6MWT has prognostic utility in elderly patients. Those who walked less than 200 m were at highest risk. Nebivolol had no effect on 6MWT.
BACKGROUND: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the effect of nebivolol on 6MWT from the SENIORS trial. METHODS AND RESULTS: The SENIORS trial evaluated nebivolol versus placebo on death and hospitalisation in patients aged ≥ 70 years with heart failure. A total of 1982 patients undertook a 6MWT at baseline and 1716 patients at 6 months. Patients were divided into tertiles (≤ 200 m, 201 to ≤ 300 m and > 300 m) and to change in distance walked between baseline and 6 months (< 0 m, 0 to < 30 m and ≥ 30 m). The primary outcome was all-cause mortality and cardiovascular hospital admission. Secondary endpoint was all-cause mortality. Baseline walk distance of ≤ 200 m incurred a greater risk of the primary and secondary outcomes (HR 1.41, CI 95% 1.17-1.69, p < 0.001) and (HR 1.37, CI 95% 1.05-1.78, p = 0.019). A decline in walk distance over 6 months was associated with increased risk of clinical events. Nebivolol had no influence on change in walk distance over 6 months. CONCLUSIONS: The 6MWT has prognostic utility in elderly patients. Those who walked less than 200 m were at highest risk. Nebivolol had no effect on 6MWT.
Authors: Gerard C M Linssen; Jesse F Veenis; Alexandra Kleberger; Marcel J W Grosfeld; Eric P Viergever; Bas M van Dalen; Wendy de Valk-Bedijn; Jorina Langerveld; Hans-Peter Brunner-La Rocca; Arno W Hoes; Jasper J Brugts Journal: Clin Res Cardiol Date: 2020-02-06 Impact factor: 5.460
Authors: Nancy S Redeker; Henry Klar Yaggi; Daniel Jacoby; Christopher S Hollenbeak; Stephen Breazeale; Samantha Conley; Youri Hwang; Joanne Iennaco; Sarah Linsky; Uzoji Nwanaji-Enwerem; Meghan O'Connell; Sangchoon Jeon Journal: Sleep Date: 2022-01-11 Impact factor: 6.313